DISCOUNT ZERTIFIKAT - VERTEX PHARMACEUTICALS | Delayed Börse Stuttgart 07:03:35 03/06/2024 BST | ||
| 359.1 EUR | -2.38% |
|
| Current month | -2.38% | ||
| 1 month | -0.18% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 359.1 | -2.38% |
| 31/05/24 | 367.8 | -0.09% |
| 30/05/24 | 368.2 | -0.20% |
| 29/05/24 | 368.9 | +0.56% |
| 28/05/24 | 366.9 | +0.24% |
Delayed Quote Börse Stuttgart
Last update June 03, 2024 at 07:03 am
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Morgan Stanley |
| WKN | ME7WV9 |
| ISIN | DE000ME7WV93 |
| Date issued | 30/01/2024 |
| Maturity | 21/06/2024 (17 Days) |
| Parity | 1 : 1 |
| Emission price | 356 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 368.9 € |
|---|---|
| Lowest since issue | 347.6 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
470.2
USD
Average target price
463.5
USD
Spread / Average Target
-1.41%
- Stock Market
- Certificates
- Certificat